Gene therapy for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new gene therapy called LX109 for wet age-related macular degeneration (nAMD). It is for patients who still need regular anti-VEGF injections, and the treatment aims to reduce how often you need those injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older
- You have active wet age-related macular degeneration (nAMD) with new blood vessels that are leaking or bleeding
- Your study eye has had at least 2 anti-VEGF injections (like Eylea or Lucentis) in the last 6 months
- Your vision in the study eye is between 20/400 and 20/40, tested by an eye chart
- You do not have other serious eye diseases like diabetic retinopathy, glaucoma that is not controlled, or a history of central serous chorioretinopathy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This trial tests a new CRISPR-based gene therapy injected into the eye to treat wet age-related macular degeneration (AMD). It aims to stop the growth of abnormal blood vessels that damage your vision.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
Hear when a new To Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.